Arrowhead Pharmaceuticals, Inc.
ARWR
株式のランク
#2365
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
株価
$59.06
最終同期: 2026-10-20
時価総額
$8.34B
変化（1日）
3.20%
変化（1年）
55.30%
国
US
取引 Arrowhead Pharmaceuticals, Inc. (ARWR)
カテゴリー
Healthcare
Arrowhead Pharmaceuticals, Inc.（ARWR）の収益
Jun 2026 時点の収益 TTM: $669.50M
Arrowhead Pharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は $669.50M です。2024 年には $3.55M の収益があり、これは 2023 年の $240.74M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Arrowhead Pharmaceuticals, Inc. の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $669.50M | -19.28% |
| 2025 | $829.45M | 23,258.15% |
| 2024 | $3.55M | -98.52% |
| 2023 | $240.74M | -1.03% |
| 2022 | $243.23M | 75.89% |
| 2021 | $138.29M | 57.16% |
| 2020 | $87.99M | -47.87% |
| 2019 | $168.80M | 945.67% |
| 2018 | $16.14M | -48.60% |
| 2017 | $31.41M | 19,736.49% |
| 2016 | $158.33K | -58.55% |
| 2015 | $382.00K | 118.29% |
| 2014 | $175.00K | -39.71% |
| 2013 | $290.27K | 97.63% |
| 2012 | $146.88K | -50.40% |
| 2011 | $296.14K | -52.24% |
| 2010 | $620.10K | -83.50% |
| 2009 | $3.76M | 188.38% |
| 2008 | $1.30M | 7.88% |
| 2007 | $1.21M | 102.87% |
| 2006 | $595.46K | 0.81% |
| 2005 | $590.68K | 200.90% |
| 2004 | $196.31K | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $2.27K | -75.67% |
| 2001 | $9.31K | -62.57% |
| 2000 | $24.88K | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,785.65% |
US
|
|
| $2.23B | 232.79% |
US
|
|
| $15.74B | 2,251.67% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 799.38% |
NL
|
